PriceTargets.com logo

NASDAQ:PAVM - PAVmed Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 114.59 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.33 As of 01/25/2021 01:00 AM ET
▲ +0.14 (6.39%)
1 month | 3 months | 12 months
Get New PAVmed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PAVM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PAVM

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$5.00
▲ +114.59% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for PAVmed in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 114.59% upside from the last price of $2.33.
Buy
The current consensus among 3 contributing investment analysts is to buy stock in PAVmed. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/4/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/5/2020Ascendiant Capital MarketsInitiated CoverageBuy$5.00Medium
i
10/13/2020Lake Street CapitalInitiated CoverageBuy$5.00Medium
i
5/30/2020Maxim GroupReiterated RatingBuy$5.00Low
i
Rating by Anthony Vendetti at Maxim Group
5/22/2020Maxim GroupReiterated RatingBuy$5.00N/A
i
Rating by Anthony Vendetti at Maxim Group
4/17/2020Maxim GroupReiterated RatingBuy$5.00High
i
Rating by Anthony Vendetti at Maxim Group
2/26/2020Maxim GroupReiterated RatingBuy$5.00High
i
Rating by Anthony Vendetti at Maxim Group
11/22/2019Maxim GroupReiterated RatingBuy$3.00Low
i
Rating by Anthony Vendetti at Maxim Group
8/16/2019Maxim GroupSet Price TargetBuy$3.00Low
i
Rating by Anthony Vendetti at Maxim Group
5/23/2019Maxim GroupReiterated RatingBuyHigh
i
4/7/2019Maxim GroupReiterated RatingBuyMedium
i
1/14/2019Maxim GroupReiterated RatingBuy$3.00Medium
i
6/28/2018Maxim GroupInitiated CoverageBuy$5.00High
i
9/5/2017Dawson JamesReiterated RatingBuy$10.10High
i
Rating by R. Wasserman at Dawson James
(Data available from 1/25/2016 forward)
PAVmed logo
PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.
Read More

Today's Range

Now: $2.33
$2.08
$2.47

50 Day Range

MA: $2.01
$1.76
$2.58

52 Week Range

Now: $2.33
$1.30
$3.45

Volume

3,870,104 shs

Average Volume

2,593,126 shs

Market Capitalization

$153.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.13

Frequently Asked Questions

What sell-side analysts currently cover shares of PAVmed?

The following Wall Street sell-side analysts have issued research reports on PAVmed in the last twelve months: Ascendiant Capital Markets, Lake Street Capital, and Maxim Group.

What is the current price target for PAVmed?

3 Wall Street analysts have set twelve-month price targets for PAVmed in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 128.3%. Maxim Group has the highest price target set, predicting PAVM will reach $5.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $5.00 for PAVmed in the next year.

What is the current consensus analyst rating for PAVmed?

PAVmed currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PAVM will outperform the market and that investors should add to their positions of PAVmed.

What other companies compete with PAVmed?

Other companies that are similar to PAVmed include Anika Therapeutics, Profound Medical, Invo Bioscience, SeaSpine, Accuray, TransEnterix, Retractable Technologies, Cytosorbents, Neuronetics, Apyx Medical, InfuSystem, ClearPoint Neuro, iCAD, UFP Technologies and Co-Diagnostics.

How do I contact PAVmed's investor relations team?

PAVmed's physical mailing address is ONE GRAND CENTRAL PLACE SUITE 4600, NEW YORK NY, 10165. The company's listed phone number is 212-949-4319 and its investor relations email address is [email protected] The official website for PAVmed is www.pavmed.com.